Integra LifeSciences Holdings Corporation (NASDAQ:IART) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue decreased its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) by 30.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,264 shares of the life sciences company's stock after selling 40,127 shares during the period. State of Alaska Department of Revenue owned 0.12% of Integra LifeSciences worth $2,006,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Quadrant Capital Group LLC boosted its stake in Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 1,371 shares in the last quarter. Sterling Capital Management LLC lifted its holdings in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after purchasing an additional 1,931 shares during the last quarter. Covestor Ltd boosted its position in shares of Integra LifeSciences by 61.8% in the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after purchasing an additional 2,071 shares during the period. NorthRock Partners LLC purchased a new position in Integra LifeSciences during the 4th quarter worth approximately $251,000. Finally, LPL Financial LLC purchased a new position in Integra LifeSciences during the 4th quarter worth approximately $255,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on IART. JMP Securities lowered their target price on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company dropped their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. JPMorgan Chase & Co. reduced their target price on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Finally, Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Four research analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, Integra LifeSciences currently has a consensus rating of "Hold" and an average target price of $18.63.

Integra LifeSciences Stock Performance

Shares of IART stock traded up $0.08 during mid-day trading on Friday, hitting $12.29. The stock had a trading volume of 1,246,403 shares, compared to its average volume of 1,004,895. The firm has a market cap of $955.06 million, a PE ratio of -32.34, a PEG ratio of 0.66 and a beta of 1.16. The company's 50-day simple moving average is $13.54 and its 200-day simple moving average is $19.47. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.21 and a quick ratio of 0.72. Integra LifeSciences Holdings Corporation has a fifty-two week low of $11.06 and a fifty-two week high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The firm had revenue of $382.65 million during the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a negative net margin of 1.78% and a positive return on equity of 12.12%. Integra LifeSciences's revenue for the quarter was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.55 EPS. Sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.